Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD) ...

Specific protein signatures could predict a future diagnosis of Crohn disease and ulcerative colitis, potentially enabling ...

The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

New research shows how metabolic activity and thus the communication between intestinal tissue and microbiome collapses ...

Welcome to the realm of irritable bowel syndrome (IBS), a prevalent and chronic disorder that affects over 1 billion ...

Pain and cramping are common with Crohn’s disease, but they don’t have to be. Try these long- and short-term tips for soothing relief.

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

Understanding these progression patterns helps physicians develop targeted treatment strategies. Research increasingly suggests that having IBD elevates the risk of developing autoimmune conditions.

One of the treatments for IBD is anti-inflammatory steroids ... offers the prospect of treatment strategies to improve the therapeutic indices of GI drugs.” They suggested that their data ...

This review aims to provide a comprehensive analysis of current evidence and emerging strategies for treatment sequencing in IBD, incorporating key clinical variables such as prior exposure to ...

the program will expand access to cutting-edge diagnostics and develop personalized treatment strategies tailored to the unique needs of children and adolescents with IBD. "Dr. Dolinger's arrival ...